Global life sciences leader Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector manufacturing technologies. CEVEC will further strengthen Cytiva's leading position in biomanufacturing solutions.

One of the pharmaceutical industry's biggest challenges in cell and gene therapy is establishing production processes that can keep up with the increasing demand for volume and consistent quality of viral vectors. With its scalable producer cell lines for vectors based on Adeno- Associated Virus (AAV) and Adenovirus, CEVEC covers two of the most widely used vectors for delivering therapeutic genes to target cells and tissues.

Producer Cell Lines (PCLs) as enabled by CEVEC's ELEVECTA Technology enable yield, scalability, and robustness in the manufacturing process. With the ELEVECTA Technology, all components necessary for vector production are stably integrated into the genome of the PCL, offering an alternative to technologies based on transfection or the use of a helper virus.

CEVEC and its 46 scientific experts will become part of Cytiva with immediate effect. CEVEC's products, services and technologies will continue to be offered under the ELEVECTA and CAP brands in the immediate future and will be available to customers worldwide.